HC Wainwright reaffirmed their buy rating on shares of Marrone Bio Innovations (NASDAQ:MBII) in a report released on Monday morning, AnalystRatings.com reports. The brokerage currently has a $2.50 price objective on the basic materials company’s stock.
“We have not yet incorporated the effect of the financing and the proposed acquisition in our model. If, and when, the transaction closes, we believe that the company’s revenues for 2019 should be expected to be higher, relative to our current expectation, by single-digit millions. Currently, we are projecting MBII to generate revenues of $30.3M in 2019. We expect revenues to reach $160.7M in 2025, growing at a six-year CAGR of 32.0%, relative to 2019 levels. We are estimating gross margin to stay at 55-56% level for the next several years.”,” HC Wainwright’s analyst wrote.
A number of other analysts have also weighed in on MBII. National Securities reaffirmed a buy rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a research report on Friday, August 9th. Aegis started coverage on Marrone Bio Innovations in a research report on Wednesday, July 24th. They set a buy rating and a $2.00 price objective on the stock.
Marrone Bio Innovations stock opened at $1.47 on Monday. Marrone Bio Innovations has a twelve month low of $1.10 and a twelve month high of $2.14. The stock’s fifty day moving average is $1.40. The company has a quick ratio of 1.47, a current ratio of 1.94 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $162.77 million, a price-to-earnings ratio of -7.00 and a beta of -0.15.
Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, August 8th. The basic materials company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Marrone Bio Innovations had a negative return on equity of 157.42% and a negative net margin of 86.09%. The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $9.01 million. On average, equities research analysts expect that Marrone Bio Innovations will post -0.18 EPS for the current year.
Several hedge funds have recently modified their holdings of MBII. BlackRock Inc. grew its stake in shares of Marrone Bio Innovations by 0.5% during the fourth quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock worth $4,117,000 after purchasing an additional 14,014 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Marrone Bio Innovations by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock worth $652,000 after purchasing an additional 24,460 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Marrone Bio Innovations during the first quarter worth $74,000. Spark Investment Management LLC grew its stake in shares of Marrone Bio Innovations by 47.5% during the first quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock worth $145,000 after purchasing an additional 30,600 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Marrone Bio Innovations during the second quarter worth $28,000. Hedge funds and other institutional investors own 42.01% of the company’s stock.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Featured Article: How is the Producer Price Index calculated?
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.